Research report: Cost-Utility Analysis of Bortezomib, Thalidomide and Lenalidomide for Relapsed/Refractory Multiple Myeloma Treatment

Home > News > Publications > Documents > Research Reports > Research report: Cost-Utility Analysis of Bortezomib, Thalidomide and Lenalidomide for Relapsed/Refractory Multiple Myeloma Treatment

Download Download 277

Views 313

Details

No details.

Top

Research report: Cost-Utility Analysis of Bortezomib, Thalidomide and Lenalidomide for Relapsed/Refractory Multiple Myeloma Treatment

Details

Menu

Follow Us On

Subscribe to our mailing list

HITAP เข้าสู่ระบบ

Research report: Cost-Utility Analysis of Bortezomib, Thalidomide and Lenalidomide for Relapsed/Refractory Multiple Myeloma Treatment

Details

Menu

Follow Us On

Subscribe to our mailing list

Subscribe to our mailing list